Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award Director acquired 10,632 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 4 Gift President and CEO gave 50,000 shares (gift)
  4. 4 Open-market sale COFO and Secretary sold 2,937 shares at $13.58 ($39,884)
  5. 4 Planned sale Chief Medical Officer sold 3,743 shares at an average $13.81 ($51,684)
  6. 4 Option exercise Chief Medical Officer acquired 44,655 shares (option exercise)
  7. 4 Planned sale President and CEO sold 495,282 shares at $15.00 ($7,429,230)
  8. 4 Grant or award Director acquired 21,130 shares (grant or award)
  9. 3 Insider Initial Statement of Ownership
  10. 3 Insider Initial Statement of Ownership
  11. 4 Grant or award Director acquired 6,037 shares (grant or award)
  12. 4 Grant or award Director acquired 6,037 shares (grant or award)
  13. 4 Grant or award Director acquired 6,037 shares (grant or award)
  14. 4 Grant or award Director acquired 6,037 shares (grant or award)
  15. 4 Grant or award Director acquired 6,037 shares (grant or award)
  16. 4 Grant or award Director acquired 6,037 shares (grant or award)
  17. 4 Grant or award Director acquired 6,037 shares (grant or award)
  18. 4 Open-market sale Chief Medical Officer sold 15,162 shares at an average $20.33 ($308,291)
  19. 4 Open-market sale COFO and Secretary sold 15,162 shares at an average $20.33 ($308,291)
  20. 4 Open-market sale President and CEO sold 36,916 shares at an average $20.34 ($750,955)

Page 2 of 22 · 436 filings